AER 1569202 is a spontaneous case, received on 24/Apr/2015 from a physician via a company representative and 
concerns a 71 year old male patient who died due to progressive multifocal leukoencephalopathy while being 
treated with rituximab (Mabthera).
No medical history, past drugs, concurrent conditions were reported. Concomitant medications included fludarabine
(Fludarabine), cyclophosphamide (Cyclophosphamide).
On an unspecified date, the patient started therapy with rituximab (dosage regimen not reported) for chronic 
lymphocytic leukemia. After the 4th course of this treatment, he developed progressive multifocal 
leukoencephalopathy which was confirmed by neurology and hematology departments.On an unspecified date, he 
passed away. The cause of death was progressive multifocal leukoencephalopathy. It was not known whether 
autopsy was performed or not.
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 366 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
A the time of death, it was not known whether the therapy with rituximab was ongoing or not.
The physician did not report a causality between fatal progressive multifocal leukoencephalopathy and rituximab.
No further information was provided
The French imputability concerning the event fatal progressive multifocal leukoencephalopathy  and rituximab is 
chronology 2 semiology 2 imputability 2.